Xtampza
Payments companies reported to CMS as associated with Xtampza. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Xtampza, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Xtampza
These are the largest totals companies reported as associated with Xtampza. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Charles Argoff | Albany, NY | Neurology (Psychiatry & Neurology) | $103,554.04 |
| Jeffrey Gudin | Miami, FL | Pain Medicine (Anesthesiology) | $95,828.40 |
| Richard Rauck | Winston Salem, NC | Pain Medicine | $66,430.47 |
| Nathaniel Schuster | San Diego, CA | Pain Medicine (Anesthesiology) | $58,350.00 |
| Martin Angst | Stanford, CA | Anesthesiology | $40,209.00 |
| Lynn Webster | Salt Lake City, UT | Pain Medicine | $18,897.22 |
| Christopher Gharibo | New York, NY | Pain Medicine (Anesthesiology) | $17,925.00 |
| Anjuli Desai | Austin, TX | Interventional Pain Medicine | $13,026.52 |
| Edward Michna | Boston, MA | Anesthesiology | $12,160.00 |
| Lonnie Zeltzer | Los Angeles, CA | Interventional Pain Medicine | $11,780.00 |
Prescribed Xtampza?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.